Aids 2026 [patched] -

In Eastern Europe and Central Asia, infection rates are rising —not falling. Why? Geopolitics. The disruption of global supply chains (exacerbated by the economic volatility of the mid-2020s) has pushed HIV treatment to the bottom of the national priority list.

You have heard the rumors about the CRISPR cure. In 2026, we are still waiting for the "London Patient" miracle to become a pharmacy product. Gene editing is expensive ($2 million per patient). It works. But it isn't scalable. aids 2026

AIDS 2026: The Last Mile of the Epidemic or a Warning from the Future? In Eastern Europe and Central Asia, infection rates

New research is focusing on the intersection of neuroHIV and Alzheimer's disease in an aging population. The disruption of global supply chains (exacerbated by

Furthermore, we are seeing a resurgence of "AIDS exceptionalism" fatigue. Donors are tired. The public is distracted by climate migration and AI wars. The result? A 15% funding cut to PEPFAR (the U.S. President's Emergency Plan for AIDS Relief) that quietly went through last fall.

The search for a functional cure is stronger than ever. The scientific community is focusing heavily on immunotherapy, investigating how "elite controllers"—individuals who maintain undetectable viral loads without medication—can help us develop a universal, scalable cure.